Common genetic variants in the myeloperoxidase and paraoxonase genes and the related cancer risk: A review

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 30, Issue 4, 2012, Pages 287-322

  Yuzhalin, Arseniy E ^a,b   Kutikhin, Anton G ^b  

^a RESEARCH INSTITUTE FOR COMPLEX ISSUES OF CARDIOVASCULAR DISEASES   (Russian Federation)

^b KEMEROVO STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

DNA damage; MPO; Myeloperoxidase; oxidative stress; paraoxonase; PON; single nucleotide polymorphism; SNP

Indexed keywords

DNA DAMAGES; MPO; MYELOPEROXIDASE; PARAOXONASE; PON; SINGLE NUCLEOTIDE POLYMORPHISMS; SNP;

DISEASES; ENZYMES; HEALTH CARE; MOLECULAR BIOLOGY; NUCLEOTIDES; OXIDATIVE STRESS; OXYGEN;

GENES;

ARYLDIALKYLPHOSPHATASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; MYELOPEROXIDASE; PROTEIN P53; SUPEROXIDE DISMUTASE;

ALLELE; BLADDER CANCER; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLORECTAL CANCER; DNA DAMAGE; DNA REPAIR; DNA SEQUENCE; DNA STRAND; ESOPHAGUS CANCER; ETHNICITY; GENETIC VARIABILITY; GENOTYPE; HEPATOBLASTOMA; HUMAN; LARYNX CANCER; LEIOMYOMA; LUNG CANCER; LYMPHATIC LEUKEMIA; LYMPHOCYTOMA; MOUTH CARCINOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OVARY CANCER; OXIDATIVE STRESS; PANCREAS CANCER; PHARYNX CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STOMACH CANCER; UTERINE CERVIX CANCER;

ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; PEROXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 84870550788     PISSN: 10590501     EISSN: 15324095     Source Type: Journal    
DOI: 10.1080/10590501.2012.731957     Document Type: Review

References (127)

1. Yuzhalin AE, Kutikhin AG. Inherited variations in the SOD and GPX gene families and cancer risk. Free Radic Res. 2012; 46(5):581-599.
2. Agner K. Verdoperoxidase. A ferment isolated from leukocytes. Acta Physiol Scand. 1941; 2:1-62.
3. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005; 77:598-625. (Pubitemid 40628741)
4. Wu X, Schabath MB, Spitz MR. Myeloperoxidase promoter region polymorphism and lung cancer risk. In: B Driscoll, Ed. Lung Cancer: Volume 2: Diagnostic and Therapeutic Methods and Reviews. Totowa, NJ: Humana Press; 2003.
5. Tsuruta Y, Subrahmanyam VV, Marshall W, O'Brien PJ. Peroxidase-mediated irreversible bindingof arylamine carcinogens to DNA in intact polymorphonuclear leukocytes activated by a tumor promoter. Chem-Biol Interact. 1985; 53:25-35. (Pubitemid 15066789)
6. Whiteman M, Jenner A, Halliwell B. Hypochlorous acid-induced base modifications in isolated calf thymus DNA. Chem Res Toxicol. 1997;10(11):1240-1246. (Pubitemid 27524829)
7. Pero RW, Sheng Y, Olsson A, Bryngelsson C, Lund-Pero M. Hypochlorous acid/Nchloramines are naturally produced DNA repair inhibitors. Carcinogenesis. 1996; 17:13-18. (Pubitemid 26091264)
8. Shen Z, Wu W, Hazen SL. Activated leukocytesoxidatively damage DNA, RNA, and the nucleotide pool through halide-dependent formationof hydroxyl radical. Biochemistry. 2000; 39(18):5474-5482. (Pubitemid 30257089)
9. Morishita K, Kubota N, Asano S, Kaziro Y, Nagata S. Molecular cloning and characterizationof cDNA for human myeloperoxidase. J Biol Chem. 1987; 262: 3844-3851. (Pubitemid 17132930)
10. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, PfahlM, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormoneretinoic acid response element. J Biol Chem. 1996; 271:14412-14420.
11. Schmekel B, Karlsson SE, Linden M, Sundstrom C, Tegner H, Venge P. Myeloperoxidase in human lung lavage. I. A markerof local neutrophil activity. Inflammation. 1990;14(4):447-454. (Pubitemid 20206257)
12. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res. 1997. 57(22):5001-5003. (Pubitemid 27498108)
13. Schabath MB, Spitz MR, Zhang X, Delclos GL, Wu X. Genetic variantsof myeloperoxidase and lung cancer risk. Carcinogenesis. 2000; 21(6):1163-1166. (Pubitemid 30389342)
14. Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Müller JM, et al. Substantially reduced riskof cancerof the aerodigestive tract in subjects with variant - 463Aof the myeloperoxidase gene. Cancer Res. 2000; 60(3):644-649. (Pubitemid 30094562)
15. Le Marchand L, Seifried A, Lum A, Wilkens LR. Associationof the myeloperoxidase -463G->a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000; 9(2):181-184. (Pubitemid 30111941)
16. Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, Benhamou S. Point: myeloperoxidase -463G -> a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002; 11(12):1550-1554. (Pubitemid 36020005)
17. Kantarci OH, Lesnick TG, Yang P, Meyer RL, Hebrink DD, McMurray CT, Weinshenker BG. Myeloperoxidase -463 (G->A) polymorphism associated with lower riskof lung cancer. Mayo Clin Proc. 2002; 77(1):17-22. (Pubitemid 34049606)
18. Dally H, Gassner K, J?ager B, Schmezer P, Spiegelhalder B, Edler L, et al. Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer. 2002; 102(5):530-535. (Pubitemid 35316010)
19. Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphismsof the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylationof the CDKN2A and RARB genes. Cancer Genet Cytogenet. 2005; 162(1):10-20. (Pubitemid 41278465)
20. Arslan S, Pinarbasi H, Silig Y. Myeloperoxidase G-463A polymorphism and riskof lung and prostate cancer in a Turkish population. Mol Med Report. 2011; 4(1):87-92.
21. Lu W, Qi J, Xing D, Tan W, Miao X, Su W, et al. Lung cancer risk associated with genetic polymorphism in myeloperoxidase (-463 G/A) in a Chinese population. [Article in Chinese]. Zhonghua Zhong Liu Za Zhi. 2002;; 24(3):250-253.
22. Misra RR, Tangrea JA, Virtamo J, Ratnasinghe D, Andersen MR, Barrett M, et al. Variation in the promoter regionof the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland. Cancer Lett. 2001; 164(2):161-167. (Pubitemid 32155504)
23. Larsen JE, Colosimo ML, Yang IA, Bowman R, Zimmerman PV, Fong KM. CYP1A1 Ile462Val and MPO G-463A interact to increase riskof adenocarcinoma but not squamous cell carcinomaof the lung. Carcinogenesis. 2006; 27(3):525-532. (Pubitemid 43372882)
24. Xu LL, Liu G, Miller DP, Zhou W, Lynch TJ, Wain JC, et al. Counterpoint: the myeloperoxidase -463G->a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev. 2002; 11(12):1555-1559. (Pubitemid 36020006)
25. Cajas-Salazar N, Sierra-Torres CH, Salama SA, Zwischenberger JB, Au WW. Combined effectof MPO, GSTM1 and GSTT1 polymorphismson chromosome aberrations and lung cancer risk. Int J Hyg Environ Health. 2003; 206(6):473-483. (Pubitemid 37322790)
26. Chevrier I, St ücker I, Houllier AM, Cenée S, Beaune P, Laurent-Puig P, Loriot MA. Myeloperoxidase: new polymorphisms and relation with lung cancer risk. Pharmacogenetics. 2003; 13(12):729-739. (Pubitemid 38429251)
27. Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen. 2004; 44(1):74-82. (Pubitemid 38982074)
28. Skuladottir H, Autrup H, Autrup J, Tjoenneland A, Overvad K, Ryberg D, et al. Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the ageof 60 years. A pooled studyof lung cancer patients in Denmark and Norway. Lung Cancer. 2005; 48(2):187-199.
29. Park JH, Park JM, Kim EJ, Cha SI, Lee EB, Kim CH, et al. Myeloperoxidase - 463G>A polymorphism and riskof primary lung cancer in a Korean population. Cancer Detect Prev. 2006; 30(3):257-261. (Pubitemid 44163049)
30. Yang M, Choi Y, Hwangbo B, Lee JS. Combined effectsof genetic polymorphisms in six selected geneson lung cancer susceptibility. Lung Cancer. 2007; 57(2):135- 142. (Pubitemid 47043185)
31. Yoon KA, Kim JH, Gil HJ, Hwang H, Hwangbo B, Lee JS. CYP1B1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women. Lung Cancer. 2008; 60(1):40-46. (Pubitemid 351434467)
32. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, et al. A comprehensive analysisof phase I and phase II metabolism gene polymorphisms and riskof non-small cell lung cancer in smokers. Carcinogenesis. 2008; 29(6):1164-1169. (Pubitemid 351958695)
33. Klinchid J, Chewaskulyoung B, Saeteng S, Lertprasertsuke N, Kasinrerk W, Cressey R. Effectof combined genetic polymorphismson lung cancer risk in northern Thai women. Cancer Genet Cytogenet. 2009; 195(2):143-149.
34. Hua F, Wang J, Gu J, Li S, LiuH, Zhou Q. A meta-analysison the relationship between myeloperoxidase G-463A genetic polymorphisms and lung cancer susceptibility. [Article in Chinese]. Zhongguo Fei Ai Za Zhi. 2010;; 13(2):122-127.
35. Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, et al. MPO and SOD2 polymorphisms, gender, and the riskof non-small cell lung carcinoma. Cancer Lett. 2004; 214(1):69-79. (Pubitemid 39141200)
36. Zhu H, Yang L, Zhou B, Yu R, Tang N, Wang B. Myeloperoxidase G-463A polymorphism and the riskof gastric cancer: a case-control study. Carcinogenesis. 2006;27(12):2491-2496. (Pubitemid 44884108)
37. Jiang Z, Zhang Z, Wang Z, Zhang G, Hu K, He B, Wang S. Associationof the 463G-A myeloperoxidase gene polymorphism with gastric cancer risk. Hepatogastroenterology. 2012; 59(115):757-761.
38. Hsu PI, Jwo JJ, Yang CL, Hsu PN, Yang HB, Lai KH, et al. Associationof the myeloperoxidase polymorphism with the riskof gastric cancer. Anticancer Res. 2008; 28(2B):1317-1323.
39. Eurogast Study Group. An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet. 1993; 341:1359-1362.
40. Choi JY, Neuhouser ML, Barnett MJ, Hong CC, Kristal AR, Thornquist MD, et al. Iron intake,oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis. 2008; 29(5):964-970. (Pubitemid 351982241)
41. Muzandu K, Shaban Z, Ishizuka M, Kazusaka A, Fujita S. Nitricoxide enhances catechol estrogen-inducedoxidative stress in LNCaP cells. Free Radic Res. 2005; 39(4):389-398. (Pubitemid 40613718)
42. Fan R, Kumaravel TS, Jalali F,Marrano P, Squire JA, Bristow RG. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res. 2004; 64(23):8526-8533. (Pubitemid 39552064)
43. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants inoxidative stress-induced cancer. Chem Biol Interact. 2006; 160(1):1-40. (Pubitemid 43227479)
44. Cheng TY, Barnett MJ, Kristal AR, Ambrosone CB, King IB, Thornquist MD, et al. Genetic variation in myeloperoxidase modifies the associationof serum α- tocopherol with aggressive prostate cancer among current smokers. J Nutr. 2011; 141(9):1731-1737.
45. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst. 2000; 92(24):2018-2023. (Pubitemid 32045898)
46. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ. Lower prostate cancer risk in men with elevated plasma lycopene levels: resultsof a prospective analysis. Cancer Res. 1999; 59(6):1225-1230. (Pubitemid 29136251)
47. Koutros S, Andreotti G, Berndt SI, Hughes Barry K, Lubin JH, Hoppin JA, et al. Xenobiotic-metabolizing gene variants, pesticide use, and the riskof prostate cancer. Pharmacogenet Genomics. 2011; 21(10):615-623.
48. Costa C, Teixeira JP, Silva S, Roma-Torres J, Coelho P, Gaspar J, et al. Cytogenetic and molecular biomonitoringof a Portuguese population exposed to pesticides. Mutagenesis. 2006; 21:343-350. (Pubitemid 44549969)
49. Lin SC, Chou YC, Wu MH, Wu CC, Lin WY, Yu CP, et al. Genetic variantsof myeloperoxidase and catechol-O-methyltransferase and breast cancer risk. Eur J Cancer Prev. 2005; 14(3):257-261.
50. Ahn J, Ambrosone CB, Kanetsky PA, Tian C, Lehman TA, Kropp S, et al. Polymorphisms in genes related tooxidative stress (CAT, MnSOD, MPO, and eNOS) and acute toxicities from radiation therapy following lumpectomy for breast cancer. Clin Cancer Res. 2006; 12(23):7063-7070. (Pubitemid 44974505)
51. Yang J, Ambrosone CB, Hong CC, Ahn J, Rodriguez C, Thun MJ, Calle EE. Relationships between polymorphisms in NOS3 and MPO genes, cigarette smoking and riskof post-menopausal breast cancer. Carcinogenesis. 2007; 28(6):1247-1253. (Pubitemid 47064311)
52. Li Y, Ambrosone CB, McCullough MJ, Ahn J, Stevens VL, Thun MJ, Hong CC. Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk. Carcinogenesis. 2009; 30(5):777-784.
53. Pabalan N, Jarjanazi H, Sung L, Li H, Ozcelik H. Menopausal status modifies breast cancer risk associated with the myeloperoxidase (MPO) G463A polymorphism in Caucasian women: a meta-analysis. PLoS One. 2012;7(3).
54. Roy D, Cai Q, Felty Q, Narayan S. Estrogen-induced generationof reactiveoxygen and nitrogen species, gene damage, and estrogen-dependent cancers. J Toxicol Environ Health B Crit Rev. 2007; 10(4):235-257. (Pubitemid 47057178)
55. Borrás C, Gambini J, Gómez-Cabrera MC, Sastre J, Pallardó FV,Mann GE, Vina J. 17beta-oestradiol up-regulates longevity-related, antioxidant enzyme expression via the ERK1 and ERK22[MAPK]/NFkappaB cascade. Aging Cell. 2005;; 4(3):113-118. (Pubitemid 41602744)
56. He C, Tamimi RM, Hankinson SE, Hunter DJ, Han J. A prospective studyof genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat. 2009; 113(3):585-594.
57. Battisti V, Maders LD, Bagatini MD, Santos KF, Spanevello RM, Maldonado PA. Measurementofoxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin Biochem. 2008; 41:511-518.
58. Schlaifer D, Duchayne E, Demur C, Alvinerie P, Muller C, Attal M, et al. Vincristine degradation by serum from leukemic patients: roleof myeloperoxidase. Leuk Lymphoma. 1996; 20(5-6):441-446. (Pubitemid 26096050)
59. Oberg G, Dahl R, Ellegaard J, Sundstrom C, Vaeth M, Venge P. Diagnostic and prognostic significanceof serum measurementsof lactoferrin, lysozyme and myeloperoxidase in acute myeloid leukemia (AML): recognitionof a new variant, highlactoferrin AML. Eur J Haematol. 1987;38:148-155.
60. Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D. Roleof NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer. 2002; 97(2):230-236. (Pubitemid 34019960)
61. Wang SS, Davis S, Cerhan JR, Hartge P, Severson RK, Cozen W, et al. Polymorphisms inoxidative stress genes and risk for non-Hodgkin lymphoma. Carcinogenesis. 2006; 27(9):1828-1834. (Pubitemid 44288664)
62. Zhang J, Zhu FY, Pu YP, Yin LH, Luo J, Wang WP, Zhou GH. Analysisof multiple single nucleotide polymorphisms (SNPs)ofmyeloperoxidase (MPO) to screen for genetic markers associated with acute leukemia in Chinese Han population. J Toxicol Environ Health A. 2007; 70(11):901-907. (Pubitemid 46699719)
63. Silveira Vda S, Canalle R, Scrideli CA, Queiroz RG, Tone LG. Roleof the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children. Environ Mol Mutagen. 2010; 51(1):48-56.
64. Saygili EI, Aksoy N, Pehlivan M, Sever T, Yilmaz M, Cimenci IG, Pehlivan S. Enzyme levels and G-463A polymorphismof myeloperoxidase in chronic lymphocytic leukemia and multiple myeloma. Leuk Lymphoma. 2009; 50(12):2030-2037.
65. Matsuo K, Hamajima N, Suzuki R, Nakamura S, Seto M, Morishima Y, Tajima K. No substantial difference in genotype frequenciesof interleukin and myeloperoxidase polymorphisms between malignant lymphoma patients and non-cancer controls. Haematologica. 2001; 86(6):602-608. (Pubitemid 32601103)
66. Barry KH, Zhang Y, Lan Q, Zahm SH, Holford TR, Leaderer B, et al. Genetic variation in metabolic genes,occupational solvent exposure, and riskof non-Hodgkin lymphoma. Am J Epidemiol. 2011; 173(4):404-413.
67. Olson SH, Carlson MD, Ostrer H, Harlap S, Stone A, Winters M, Ambrosone CB. Genetic variants in SOD2, MPO, and NQO1, and riskofovarian cancer. Gynecol Oncol. 2004; 93(3):615-620. (Pubitemid 38766044)
68. Wheatley-Price P, Asomaning K, Reid A, Zhai R, Su L, Zhou W, et al. Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased riskof developing pancreatic adenocarcinoma. Cancer. 2008; 112(5):1037-1042. (Pubitemid 351304587)
69. Li Y, Qin Y, Wang ML, Zhu HF, Huang XE. The myeloperoxidase-463 G>A polymorphism influences riskof colorectal cancer in southern China: a case-control study. Asian Pac J Cancer Prev. 2011; 12(7):1789-1793.
70. Pakakasama S, Chen TT, Frawley W, Muller C, Douglass EC, Tomlinson GE. Myeloperoxidase promotor polymorphism and riskof hepatoblastoma. Int J Cancer. 2003; 106(2):205-207. (Pubitemid 36835172)
71. Buch SC, Nazar-Stewart V, Weissfeld JL, Romkes M. Case-control studyoforal andoropharyngeal cancer in whites and genetic variation in eight metabolic enzymes. Head Neck. 2008; 30(9):1139-1147.
72. Hsieh YY, Chang CC, Wang YK, Hsu KH, Chen CP, Hsu CM, Tsai FJ. Insulinlike growth factors II exon 9 and E-cadherin-Pml I but not myeloperoxidase promoter- 463, urokinase-ApaL I nor xeroderma pigmentosum polymorphisms are associated with higher susceptibility to leiomyoma. Anticancer Res. 2010; 30(6):2203-2208.
73. Oliveira ID, Petrilli AS, Tavela MH, Zago MA, de Toledo SR. TNF-alpha, TNFbeta, IL-6, IL-10, PECAM-1 and the MPO inflammatory gene polymorphisms inosteosarcoma. J Pediatr Hematol Oncol. 2007; 29(5):293-297. (Pubitemid 46707507)
74. Li D, Diao Y, Li H, Fang X, Li H. Associationof the polymorphismsof MTHFR C677T, VDR C352T, and MPO G463A with risk for esophageal squamous cell dysplasia and carcinoma. Arch Med Res. 2008; 39(6):594-600.
75. Matsuo K, Hamajima N, Shinoda M, Hatooka S, Inoue M, Takezaki T, et al. Possible risk reduction in esophageal cancer associated with MPO -463 A allele. J Epidemiol. 2001; 11(3):109-114. (Pubitemid 33798354)
76. Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, et al. Genetic polymorphismsof MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis. 2004; 25(6):973-978. (Pubitemid 38886083)
77. Figueroa JD, Malats N, García-Closas M, Real FX, Silverman D, Kogevinas M, et al. Bladder cancer risk and genetic variation in AKR1C3 andother metabolizing genes. Carcinogenesis. 2008; 29(10):1955-1962.
78. Mustea A, Heinze G, Sehouli J, Koensgen D, Wolf A, Gutu L, et al. The -463G/A polymorphism in myeloperoxidase gene and cervical cancer. Anticancer Res. 2007; 27(3B):1531-1535. (Pubitemid 46807233)
79. Nishino K, Sekine M, Kodama S, Sudo N, Aoki Y, Seki N, Tanaka K. Cigarette smoking and glutathione S-transferase M1 polymorphism associated with risk for uterine cervical cancer. J Obstet Gynaecol Res. 2008; 34(6):994-1001.
80. Chu H, Wang M, Wang M, Gu D, Wu D, Zhang Z, et al. The MPO -463G>A polymorphism and cancer risk: a meta-analysis basedon 43 case-control studies. Mutagenesis. 2010; 25(4):389-395.
81. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol. 1998; 31:329-336. (Pubitemid 28398854)
82. Cowan J, Sinton CM, Varley AW, Wians FH, Haley RW, Munford RS. Gene therapy to preventorganophosphate intoxication. Toxicol Appl Pharmacol. 2001; 173(1):1-6.
83. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated byoxidized lipids. Arterioscler Thromb Vasc Biol. 2001;21(4):542-547. (Pubitemid 32323386)
84. Chander R, Kapoor NK. High-density lipoprotein is a scavengerof superoxide anions. Biochem Pharmacol. 1990; 40:1663-1665. (Pubitemid 20310588)
85. Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashor S, Husain SA. Lipid peroxidation, free radical, and antioxidant status in breast cancer. Breast Cancer Res Treat. 2005; 59:163-170.
86. Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, et al. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene. 1998; 213(1-2):149-157. (Pubitemid 28284734)
87. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capableof preventing cell-mediatedoxidative modificationof low density lipoprotein. J Biol Chem. 2001; 276(48):44444-44449.
88. Akçay MN, Polat MF, Yilmaz I, Akçay G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology. 2003; 50 (Suppl. 2):ccxxv-ccxxvii.
89. Akçay MN, Yilmaz I, Polat MF, Akçay G. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology. 2003;50 (Suppl. 2):cclxxiii-cclxxv.
90. Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer. 2007; 7:48.
91. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible toorganophosphate toxicity and atherosclerosis. Nature. 1998; 394(6690):284-287. (Pubitemid 28335041)
92. Ozt ürk O, Kägnici OF, Ozt ürk T, Durak H, Tüz üner BM, Kisakesen HI, et al. 192R alleleof paraoxanase 1 (PON1) gene as a new marker for susceptibility to bladder cancer. Anticancer Res. 2009; 29(10):4041-4046.
93. Lower GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. NAcetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology: preliminary results in Sweden and Denmark. Int J Epidemiol. 2007; 36(1):11-18. (Pubitemid 47064254)
94. Leviev I, Deakin S, James RW. Decreased stabilityof the M54 isoformof paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res. 2001; 42(4):528-535. (Pubitemid 32366995)
95. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basisof the human serum paraoxonase activity polymorphism. Nat Genet. 1993; 3(1):73-76. (Pubitemid 23063292)
96. Ferré N, Camps J, Fernández-Ballart J, Arija V, Murphy MM, Ceruelo S, et al. Regulationof serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem. 2003; 49(9):1491-1497. (Pubitemid 37011737)
97. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, et al. Catalytic efficiency determines the in-vivo efficacyof PON1 for detoxifyingorganophosphorus compounds. Pharmacogenetics. 2000; 10:767-779. (Pubitemid 32042829)
98. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effectof the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet. 1996; 14:334-336.
99. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effectof the human serum paraoxonase 55 and 192 genetic polymorphismson the protection by high density lipoprotein against low density lipoproteinoxidative modification. FEBS Lett. 1998; 423: 57-60. (Pubitemid 28098579)
100. Stevens VL, Rodriguez C, Pavluck AL, Thun MJ, Calle EE. Associationof polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2006; 15(6):1226-1228.
101. Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, Helzlsouer KJ. Body mass, polymorphisms inobesity-related genes, and the riskof developing breast cancer among women with benign breast disease. Cancer Detect Prev. 2007; 31(2):95-101. (Pubitemid 46669815)
102. Stoltz DA, Ozer EA, Recker TJ, Estin M, Yang X, Shih DM, et al. A common mutation in paraoxonase-2 results in impaired lactonase activity. J Biol Chem. 2009; 284(51):35564-35571.
103. Hegele RA, Connelly PW, Scherer SW, Hanley AJ, Harris SB, Tsui LC, Zinman B. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997; 82(10):3373-3377. (Pubitemid 27419090)
104. Antognelli C, Del Buono C, Ludovini V, Gori S, Talesa VN, Crinò L, et al. CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer. 2009; 9:115.
105. Naidu R, Har YC, Taib NA. Genetic polymorphismsof paraoxonase 1 (PON1) gene: association between L55Mor Q192R with breast cancer risk and clinicopathological parameters. Pathol Oncol Res. 2010; 16(4):533-540.
106. Hussein YM, Gharib AF, Etewa RL, El Sawy WH. Associationof L55M and Q192R polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance. Mol Cell Biochem. 2011; 351(1-2):117-123.
107. Liu C, Liu L. Polymorphisms in threeobesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis. Tumour Biol. 2011; 32(6):1233-1240.
108. Provost D, Cantagrel A, Lebailly P, Jaffre A, Loyant V, Loiseau H, et al. Brain tumours and exposure to pesticides: a case control study in southwestern France. Occup Environ Med. 2007; 64(8):509-514. (Pubitemid 47195168)
109. Smith-Rooker JL, Garrett A, Hodges LC, Shue V. Prevalenceof glioblastoma multiforme subjects with prior herbicide exposure. J Neurosci Nurs. 1992; 24(5):260-264.
110. Guizzetti M, Pathak S, Giordano G, Costa LG. Effectoforganophosphorus insecticides and their metaboliteson astroglial cell proliferation. Toxicology. 2005; 215(3):182-190. (Pubitemid 41446320)
111. Nielsen S, Mueller BA, De Roos AJ, Viernes HM, Farin FM, Checkoway H. Riskof brain tumors in children and susceptibility toorganophosphorus insecticides: the potential roleof paraoxonase (PON1). Environ Health Perspect. 2005; 113(7):909- 913. (Pubitemid 40984194)
112. Searles Nielsen S, McKean-Cowdin R, Farin FM, Holly EA, Preston-Martin S, Mueller BA. Childhood brain tumors, residential insecticide exposure, and pesticide metabolism genes. Environ Health Perspect. 2010; 118(1):144-149.
113. Rajaraman P, Hutchinson A, Rothman N, Black PM, Fine HA, Loeffler JS, et al. Oxidative response gene polymorphisms and riskof adult brain tumors. Neuro Oncol. 2008; 10(5):709-715.
114. Martinez C, Molina JA, Alonso-Navarro H, Jimenez-Jimenez FJ, Agundez JA, Garcia-Martin E. Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurol. 2010; 10:71.
115. Kafadar AM, Ergen A, Zeybek U, Agachan B, Kuday C, Isbir T. Paraoxonase 192 gene polymorphism and serum paraoxonase activity in high grade gliomas and meningiomas. Cell Biochem Funct. 2006; 24(5):455-460. (Pubitemid 44379586)
116. Marchesani M, Hakkarainen A, Tuomainen TP, Kaikkonen J, Pukkala E, Uimari P, et al. New paraoxonase 1 polymorphism I102V and the riskof prostate cancer in Finnish men. J Natl Cancer Inst. 2003; 95(11):812-818. (Pubitemid 36798428)
117. Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. Associationof CYP17, GSTP1, and PON1 polymorphisms with the riskof prostate cancer. Prostate. 2005; 63(3):240-251. (Pubitemid 40571058)
118. Stevens VL, Rodriguez C, Talbot JT, Pavluck AL, Thun MJ, Calle EE. Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II nutrition cohort. Prostate. 2008; 68(12):1336-1340.
119. Lurie G,Wilkens LR, Thompson PJ, McDuffie KE, CarneyME, Terada KY, Goodman MT. Genetic polymorphisms in the Paraoxonase 1 gene and riskofovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev. 2008; 17(8):2070-2077.
120. Arpaci A, Gormüs U, Dalan B, Berkman S, Isbir T. Investigationof PON1 192 and PON1 55 polymorphisms inovarian cancer patients in Turkish population. In Vivo. 2009; 23(3):421-424.
121. Uyar OA, Kara M, Erol D, Ardicoglu A, Yuce H. Investigating paraoxonase-1 gene Q192R and L55M polymorphism in patients with renal cell cancer. Genet Mol Res. 2011; 10(1):133-139.
122. Aksoy-Sagirli P, Cakmakoglu B, Isbir T, Kaytan-Saglam E, Kizir A, Topuz E, Berkkan H. Paraoxonase-1 192/55 polymorphisms and the riskof lung cancer in a Turkish population. Anticancer Res. 2011; 31(6):2225-2229.
123. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol. 2002; 118(2):477-481. (Pubitemid 34994652)
124. Gold LS, De Roos AJ, Brown EE, Lan Q,Milliken K, Davis S, et al. Associationsof common variants in genes involved in metabolism and response to exogenous chemicals with riskof multiple myeloma. Cancer Epidemiol. 2009; 33(3-4):276-280.
125. Van Der Logt EM, Janssen CH, Van Hooijdonk Z, Roelofs HM, Wobbes T, Nagengast FM, Peters WH. No association between genetic polymorphisms in NAD(P)Hoxidase p22phox and paraoxonase 1 and colorectal cancer risk. Anticancer Res. 2005; 25(2B):1465-1470. (Pubitemid 40546830)
126. De Roos AJ, Gold LS, Wang S, Hartge P, Cerhan JR, Cozen W, et al. Metabolic gene variants and riskof non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(9):1647-1653. (Pubitemid 44497100)
127. Fang DH, Fan CH, Ji Q, Qi BX, Li J, Wang L. Differential effectsof paraoxonase 1 (PON1) polymorphismson cancer risk: evidence from 25 published studies. Mol Biol Rep. 2012; 39(6):6801-6809.